| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acute myeloid leukemia patient with active disseminated tuberculosis bridged to transplant with reduced 14-day venetoclax and azacitidine schedule
|
Lentner, Theresa
|
|
|
17 |
Suppl 5 |
p. 67-70
|
article
|
| 2 |
Antibody–drug conjugates in ovarian cancer
|
Feroz, Barin
|
|
|
17 |
Suppl 5 |
p. 130-134
|
article
|
| 3 |
Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline
|
Bir Yücel, Kadriye
|
|
|
17 |
Suppl 5 |
p. 302-306
|
article
|
| 4 |
Diagnosis and management of mediastinal extragonadal germ cell tumors
|
Heidenreich, Axel
|
|
|
17 |
Suppl 5 |
p. 123-129
|
article
|
| 5 |
GATA2 deficiency: a mystery myelodysplasia
|
Shoaib, Raqiya
|
|
|
17 |
Suppl 5 |
p. 315-321
|
article
|
| 6 |
Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice
|
Brand, Rosa
|
|
|
17 |
Suppl 5 |
p. 269-273
|
article
|
| 7 |
Importance of allogeneic stem cell transplantation in myelofibrosis
|
Hirschbühl, Klaus
|
|
|
17 |
Suppl 5 |
p. 215-219
|
article
|
| 8 |
KRAS: Finally a druggable target in oncology?
|
Ilhan-Mutlu, Aysegul
|
|
|
17 |
Suppl 5 |
p. 239
|
article
|
| 9 |
New therapy options for myelodysplastic syndrome—all for all or targeted?
|
Petzer, Verena
|
|
|
17 |
Suppl 5 |
p. 254-256
|
article
|
| 10 |
OeGHO annual meeting 2023—best of oncology
|
Pichler, Martin
|
|
|
17 |
Suppl 5 |
p. 2-3
|
article
|
| 11 |
Prognostic factors of long-term survivors with unresectable pancreatic cancer: a retrospective analysis
|
Colloca, Giuseppe A.
|
|
|
17 |
Suppl 5 |
p. 146-151
|
article
|
| 12 |
Prostate cancer special—part 2
|
Shariat, Shahrokh F.
|
|
|
17 |
Suppl 5 |
p. 4-5
|
article
|
| 13 |
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
|
Doleschal, Bernhard
|
|
|
17 |
Suppl 5 |
p. 292-296
|
article
|
Journal description